MA5-13461 targets p21WAF1 in IF and WB applications and shows reactivity with Human and Rat samples.
The MA5-13461 immunogen is human recombinant p21 protein.
Protein p21 is a tumor suppressor protein which is an inhibitor of Cyclin-dependent kinases (CDK) and is transcriptionally activated by p53. P21 is important in the response of cells to genotoxic stress and a major transcriptional target of p53 protein. The occurrence of p21 in the nucleus executes binding and inhibition activity of cyclin dependent kinases Cdk1 and Cdk2, and blocks the transition from G1 phase into S phase or from G2 phase into mitosis after DNA damage, which enables the repair of damaged DNA. In the cytoplasm, p21 protein has an anti-apoptotic effect. P21 is able to bind to and inhibit caspase 3, as well as the apoptotic kinases ASK1 and JNK. P21 exhibits a dual function in carcinogenesis, and acts as a tumor suppressor, prevents apoptosis, and acts as an oncogene.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: CAP20; CDK-interacting protein 1; CDK-interaction protein 1; CDKN1; CDNK1A; Cyclin-dependent kinase inhibitor 1; cyclin-dependent kinase inhibitor 1A (P21); cyclin-dependent kinase inhibitor 1A (p21, Cip1); DNA synthesis inhibitor; MDA-6; melanoma differentiation associated protein 6; Melanoma differentiation-associated protein 6; p21; p21CIP1; SDI1; WAF1; wild-type p53-activated fragment 1
Gene Aliases: CAP20; CDKN1; CDKN1A; CIP1; MDA-6; MDA6; P21; p21CIP1; PIC1; SDI1; UV96; WAF1
UniProt ID: (Human) P38936